Cargando…

Lactosylated Albumin Nanoparticles: Potential Drug Nanovehicles with Selective Targeting Toward an In Vitro Model of Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) ranks fifth in occurrence and second in mortality of all cancers. The development of effective therapies for HCC is urgently needed. Anticancer drugs targeted to the liver-specific asialoglycoprotein receptors (ASGPRs) are viewed as a promising potential treatment for...

Descripción completa

Detalles Bibliográficos
Autores principales: Teran-Saavedra, Nayelli Guadalupe, Sarabia-Sainz, Jose Andre-i, Silva-Campa, Erika, Burgara-Estrella, Alexel J., Guzmán-Partida, Ana María, Ramos-Clamont Montfort, Gabriela, Pedroza-Montero, Martín, Vazquez-Moreno, Luz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479765/
https://www.ncbi.nlm.nih.gov/pubmed/30970533
http://dx.doi.org/10.3390/molecules24071382
_version_ 1783413420657213440
author Teran-Saavedra, Nayelli Guadalupe
Sarabia-Sainz, Jose Andre-i
Silva-Campa, Erika
Burgara-Estrella, Alexel J.
Guzmán-Partida, Ana María
Ramos-Clamont Montfort, Gabriela
Pedroza-Montero, Martín
Vazquez-Moreno, Luz
author_facet Teran-Saavedra, Nayelli Guadalupe
Sarabia-Sainz, Jose Andre-i
Silva-Campa, Erika
Burgara-Estrella, Alexel J.
Guzmán-Partida, Ana María
Ramos-Clamont Montfort, Gabriela
Pedroza-Montero, Martín
Vazquez-Moreno, Luz
author_sort Teran-Saavedra, Nayelli Guadalupe
collection PubMed
description Hepatocellular carcinoma (HCC) ranks fifth in occurrence and second in mortality of all cancers. The development of effective therapies for HCC is urgently needed. Anticancer drugs targeted to the liver-specific asialoglycoprotein receptors (ASGPRs) are viewed as a promising potential treatment for HCC. ASGPRs facilitate the recognition and endocytosis of molecules, and possibly vehicles with galactose end groups, by the liver. In this study, bovine serum albumin (BSA) was conjugated with lactose using a thermal treatment. The formation of lactosylated BSA (BSA-Lac) was confirmed by a change of the chemical structure, increased molecular mass, and Ricinus communis lectin recognition. Subsequently, the low-crosslinking BSA-Lac nanoparticles (LC BSA-Lac NPs) and high-crosslinking BSA-Lac nanoparticles (HC BSA-Lac NPs) were synthesized. These nanoparticles presented spherical shapes with a size distribution of 560 ± 18.0 nm and 539 ± 9.0 nm, as well as an estimated surface charge of −26 ± 0.15 mV and −24 ± 0.45 mV, respectively. Both BSA-Lac NPs were selectively recognized by ASGPRs as shown by biorecognition, competition, and inhibition assays using an in vitro model of HCC. This justifies pursuing the strategy of using BSA-Lac NPs as potential drug nanovehicles with selective direction toward hepatocellular carcinoma.
format Online
Article
Text
id pubmed-6479765
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64797652019-04-30 Lactosylated Albumin Nanoparticles: Potential Drug Nanovehicles with Selective Targeting Toward an In Vitro Model of Hepatocellular Carcinoma Teran-Saavedra, Nayelli Guadalupe Sarabia-Sainz, Jose Andre-i Silva-Campa, Erika Burgara-Estrella, Alexel J. Guzmán-Partida, Ana María Ramos-Clamont Montfort, Gabriela Pedroza-Montero, Martín Vazquez-Moreno, Luz Molecules Article Hepatocellular carcinoma (HCC) ranks fifth in occurrence and second in mortality of all cancers. The development of effective therapies for HCC is urgently needed. Anticancer drugs targeted to the liver-specific asialoglycoprotein receptors (ASGPRs) are viewed as a promising potential treatment for HCC. ASGPRs facilitate the recognition and endocytosis of molecules, and possibly vehicles with galactose end groups, by the liver. In this study, bovine serum albumin (BSA) was conjugated with lactose using a thermal treatment. The formation of lactosylated BSA (BSA-Lac) was confirmed by a change of the chemical structure, increased molecular mass, and Ricinus communis lectin recognition. Subsequently, the low-crosslinking BSA-Lac nanoparticles (LC BSA-Lac NPs) and high-crosslinking BSA-Lac nanoparticles (HC BSA-Lac NPs) were synthesized. These nanoparticles presented spherical shapes with a size distribution of 560 ± 18.0 nm and 539 ± 9.0 nm, as well as an estimated surface charge of −26 ± 0.15 mV and −24 ± 0.45 mV, respectively. Both BSA-Lac NPs were selectively recognized by ASGPRs as shown by biorecognition, competition, and inhibition assays using an in vitro model of HCC. This justifies pursuing the strategy of using BSA-Lac NPs as potential drug nanovehicles with selective direction toward hepatocellular carcinoma. MDPI 2019-04-09 /pmc/articles/PMC6479765/ /pubmed/30970533 http://dx.doi.org/10.3390/molecules24071382 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Teran-Saavedra, Nayelli Guadalupe
Sarabia-Sainz, Jose Andre-i
Silva-Campa, Erika
Burgara-Estrella, Alexel J.
Guzmán-Partida, Ana María
Ramos-Clamont Montfort, Gabriela
Pedroza-Montero, Martín
Vazquez-Moreno, Luz
Lactosylated Albumin Nanoparticles: Potential Drug Nanovehicles with Selective Targeting Toward an In Vitro Model of Hepatocellular Carcinoma
title Lactosylated Albumin Nanoparticles: Potential Drug Nanovehicles with Selective Targeting Toward an In Vitro Model of Hepatocellular Carcinoma
title_full Lactosylated Albumin Nanoparticles: Potential Drug Nanovehicles with Selective Targeting Toward an In Vitro Model of Hepatocellular Carcinoma
title_fullStr Lactosylated Albumin Nanoparticles: Potential Drug Nanovehicles with Selective Targeting Toward an In Vitro Model of Hepatocellular Carcinoma
title_full_unstemmed Lactosylated Albumin Nanoparticles: Potential Drug Nanovehicles with Selective Targeting Toward an In Vitro Model of Hepatocellular Carcinoma
title_short Lactosylated Albumin Nanoparticles: Potential Drug Nanovehicles with Selective Targeting Toward an In Vitro Model of Hepatocellular Carcinoma
title_sort lactosylated albumin nanoparticles: potential drug nanovehicles with selective targeting toward an in vitro model of hepatocellular carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479765/
https://www.ncbi.nlm.nih.gov/pubmed/30970533
http://dx.doi.org/10.3390/molecules24071382
work_keys_str_mv AT teransaavedranayelliguadalupe lactosylatedalbuminnanoparticlespotentialdrugnanovehicleswithselectivetargetingtowardaninvitromodelofhepatocellularcarcinoma
AT sarabiasainzjoseandrei lactosylatedalbuminnanoparticlespotentialdrugnanovehicleswithselectivetargetingtowardaninvitromodelofhepatocellularcarcinoma
AT silvacampaerika lactosylatedalbuminnanoparticlespotentialdrugnanovehicleswithselectivetargetingtowardaninvitromodelofhepatocellularcarcinoma
AT burgaraestrellaalexelj lactosylatedalbuminnanoparticlespotentialdrugnanovehicleswithselectivetargetingtowardaninvitromodelofhepatocellularcarcinoma
AT guzmanpartidaanamaria lactosylatedalbuminnanoparticlespotentialdrugnanovehicleswithselectivetargetingtowardaninvitromodelofhepatocellularcarcinoma
AT ramosclamontmontfortgabriela lactosylatedalbuminnanoparticlespotentialdrugnanovehicleswithselectivetargetingtowardaninvitromodelofhepatocellularcarcinoma
AT pedrozamonteromartin lactosylatedalbuminnanoparticlespotentialdrugnanovehicleswithselectivetargetingtowardaninvitromodelofhepatocellularcarcinoma
AT vazquezmorenoluz lactosylatedalbuminnanoparticlespotentialdrugnanovehicleswithselectivetargetingtowardaninvitromodelofhepatocellularcarcinoma